CDCA5 promotes the progression of breast cancer and serves as a potential prognostic biomarker
Cell division cycle-associated 5 (CDCA5) plays a critical role in the progression of various human cancers by regulating cell cycle-related proteins; however, the function of CDCA5 in breast cancer (BC) is poorly understood. The aim of the present study was to investigate the expression level of CDC...
Gespeichert in:
| Veröffentlicht in: | Oncology reports 2022-10, Vol.48 (4), Article 172 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 4 |
| container_start_page | |
| container_title | Oncology reports |
| container_volume | 48 |
| creator | Hu, Hao Xiang, Yuan Zhang, Xiao-Yu Deng, Yang Wan, Fu-Jian Huang, You Liao, Xing-Hua Zhang, Tong-Cun |
| description | Cell division cycle-associated 5 (CDCA5) plays a critical role in the progression of various human cancers by regulating cell cycle-related proteins; however, the function of CDCA5 in breast cancer (BC) is poorly understood. The aim of the present study was to investigate the expression level of CDCA5 in BC and its effect on BC progression. CDCA5 was found to be highly expressed in patients with BC, as well as in BC cell lines. It was also found that a high CDCA5 expression in BC was significantly associated with a shorter survival rate. In addition, the expression level of CDCA5 was significantly increased in stem cells derived from suspension-cultured BC cells, as compared to adherent-cultured cells. CDCA5 knockdown in MCF7 and SKBR3 cells significantly reduced cell proliferation, migration and clone formation. At the same time, the stemness capacity of BC cells, determined by analyzing cancer stem cell marker expression and mammosphere formation, was also markedly diminished following the knockdown of CDCA5. In addition, in vivo experiments demonstrated that CDCA5 knockdown in MCF7 cells markedly reduced tumor growth. On the whole, the present study demonstrates that CDCA5 may be used as a prognostic biomarker and therapeutic target for BC. |
| doi_str_mv | 10.3892/or.2022.8387 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9478967</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2706719622</sourcerecordid><originalsourceid>FETCH-LOGICAL-c459t-3d767b7798f2664cd7b59ac98a5b18ef492ee696c7a15a66c0d39062e6fd4ae53</originalsourceid><addsrcrecordid>eNpdkUtLAzEUhYMotj52_oCAGxdOzWuSyUYo9QkFNwquDJnMnTo6ndRkWvDfm7EiKFzIveS7h5MchE4omfBCswsfJowwNil4oXbQmCpNMyY43U09YTTjPH8eoYMY3whhiki9j0ZcEiKEImP0MruaTXO8Cn7pe4i4f4VhWASIsfEd9jUuA9jYY2c7BwHbrsIRwiaxNhVepbWub2z7vdb52DcOl41f2vAO4Qjt1baNcPxzHqKnm-vH2V02f7i9n03nmRO57jNeKalKpXRRMymFq1SZa-t0YfOSFlALzQCklk5ZmlspHam4JpKBrCthIeeH6HKru1qXS6hcshRsa1ahST4-jbeN-XvTNa9m4TdGC1VoqZLA2Y9A8B9riL1ZNtFB29oO_Dqa4ecU1ZKxhJ7-Q9_8OnTpeYmiUgiicp6o8y3lgo8xQP1rhhIzBGd8MENwZgiOfwFI84sY</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2716440753</pqid></control><display><type>article</type><title>CDCA5 promotes the progression of breast cancer and serves as a potential prognostic biomarker</title><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Hu, Hao ; Xiang, Yuan ; Zhang, Xiao-Yu ; Deng, Yang ; Wan, Fu-Jian ; Huang, You ; Liao, Xing-Hua ; Zhang, Tong-Cun</creator><creatorcontrib>Hu, Hao ; Xiang, Yuan ; Zhang, Xiao-Yu ; Deng, Yang ; Wan, Fu-Jian ; Huang, You ; Liao, Xing-Hua ; Zhang, Tong-Cun</creatorcontrib><description>Cell division cycle-associated 5 (CDCA5) plays a critical role in the progression of various human cancers by regulating cell cycle-related proteins; however, the function of CDCA5 in breast cancer (BC) is poorly understood. The aim of the present study was to investigate the expression level of CDCA5 in BC and its effect on BC progression. CDCA5 was found to be highly expressed in patients with BC, as well as in BC cell lines. It was also found that a high CDCA5 expression in BC was significantly associated with a shorter survival rate. In addition, the expression level of CDCA5 was significantly increased in stem cells derived from suspension-cultured BC cells, as compared to adherent-cultured cells. CDCA5 knockdown in MCF7 and SKBR3 cells significantly reduced cell proliferation, migration and clone formation. At the same time, the stemness capacity of BC cells, determined by analyzing cancer stem cell marker expression and mammosphere formation, was also markedly diminished following the knockdown of CDCA5. In addition, in vivo experiments demonstrated that CDCA5 knockdown in MCF7 cells markedly reduced tumor growth. On the whole, the present study demonstrates that CDCA5 may be used as a prognostic biomarker and therapeutic target for BC.</description><identifier>ISSN: 1021-335X</identifier><identifier>EISSN: 1791-2431</identifier><identifier>DOI: 10.3892/or.2022.8387</identifier><identifier>PMID: 36004470</identifier><language>eng</language><publisher>Athens: Spandidos Publications UK Ltd</publisher><subject>Biomarkers ; Biotechnology ; Breast cancer ; Cell growth ; Kinases ; Medical prognosis</subject><ispartof>Oncology reports, 2022-10, Vol.48 (4), Article 172</ispartof><rights>Copyright Spandidos Publications UK Ltd. 2022</rights><rights>Copyright: © Hu et al. 2022</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c459t-3d767b7798f2664cd7b59ac98a5b18ef492ee696c7a15a66c0d39062e6fd4ae53</citedby><cites>FETCH-LOGICAL-c459t-3d767b7798f2664cd7b59ac98a5b18ef492ee696c7a15a66c0d39062e6fd4ae53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids></links><search><creatorcontrib>Hu, Hao</creatorcontrib><creatorcontrib>Xiang, Yuan</creatorcontrib><creatorcontrib>Zhang, Xiao-Yu</creatorcontrib><creatorcontrib>Deng, Yang</creatorcontrib><creatorcontrib>Wan, Fu-Jian</creatorcontrib><creatorcontrib>Huang, You</creatorcontrib><creatorcontrib>Liao, Xing-Hua</creatorcontrib><creatorcontrib>Zhang, Tong-Cun</creatorcontrib><title>CDCA5 promotes the progression of breast cancer and serves as a potential prognostic biomarker</title><title>Oncology reports</title><description>Cell division cycle-associated 5 (CDCA5) plays a critical role in the progression of various human cancers by regulating cell cycle-related proteins; however, the function of CDCA5 in breast cancer (BC) is poorly understood. The aim of the present study was to investigate the expression level of CDCA5 in BC and its effect on BC progression. CDCA5 was found to be highly expressed in patients with BC, as well as in BC cell lines. It was also found that a high CDCA5 expression in BC was significantly associated with a shorter survival rate. In addition, the expression level of CDCA5 was significantly increased in stem cells derived from suspension-cultured BC cells, as compared to adherent-cultured cells. CDCA5 knockdown in MCF7 and SKBR3 cells significantly reduced cell proliferation, migration and clone formation. At the same time, the stemness capacity of BC cells, determined by analyzing cancer stem cell marker expression and mammosphere formation, was also markedly diminished following the knockdown of CDCA5. In addition, in vivo experiments demonstrated that CDCA5 knockdown in MCF7 cells markedly reduced tumor growth. On the whole, the present study demonstrates that CDCA5 may be used as a prognostic biomarker and therapeutic target for BC.</description><subject>Biomarkers</subject><subject>Biotechnology</subject><subject>Breast cancer</subject><subject>Cell growth</subject><subject>Kinases</subject><subject>Medical prognosis</subject><issn>1021-335X</issn><issn>1791-2431</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>BENPR</sourceid><recordid>eNpdkUtLAzEUhYMotj52_oCAGxdOzWuSyUYo9QkFNwquDJnMnTo6ndRkWvDfm7EiKFzIveS7h5MchE4omfBCswsfJowwNil4oXbQmCpNMyY43U09YTTjPH8eoYMY3whhiki9j0ZcEiKEImP0MruaTXO8Cn7pe4i4f4VhWASIsfEd9jUuA9jYY2c7BwHbrsIRwiaxNhVepbWub2z7vdb52DcOl41f2vAO4Qjt1baNcPxzHqKnm-vH2V02f7i9n03nmRO57jNeKalKpXRRMymFq1SZa-t0YfOSFlALzQCklk5ZmlspHam4JpKBrCthIeeH6HKru1qXS6hcshRsa1ahST4-jbeN-XvTNa9m4TdGC1VoqZLA2Y9A8B9riL1ZNtFB29oO_Dqa4ecU1ZKxhJ7-Q9_8OnTpeYmiUgiicp6o8y3lgo8xQP1rhhIzBGd8MENwZgiOfwFI84sY</recordid><startdate>20221001</startdate><enddate>20221001</enddate><creator>Hu, Hao</creator><creator>Xiang, Yuan</creator><creator>Zhang, Xiao-Yu</creator><creator>Deng, Yang</creator><creator>Wan, Fu-Jian</creator><creator>Huang, You</creator><creator>Liao, Xing-Hua</creator><creator>Zhang, Tong-Cun</creator><general>Spandidos Publications UK Ltd</general><general>D.A. Spandidos</general><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20221001</creationdate><title>CDCA5 promotes the progression of breast cancer and serves as a potential prognostic biomarker</title><author>Hu, Hao ; Xiang, Yuan ; Zhang, Xiao-Yu ; Deng, Yang ; Wan, Fu-Jian ; Huang, You ; Liao, Xing-Hua ; Zhang, Tong-Cun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c459t-3d767b7798f2664cd7b59ac98a5b18ef492ee696c7a15a66c0d39062e6fd4ae53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomarkers</topic><topic>Biotechnology</topic><topic>Breast cancer</topic><topic>Cell growth</topic><topic>Kinases</topic><topic>Medical prognosis</topic><toplevel>online_resources</toplevel><creatorcontrib>Hu, Hao</creatorcontrib><creatorcontrib>Xiang, Yuan</creatorcontrib><creatorcontrib>Zhang, Xiao-Yu</creatorcontrib><creatorcontrib>Deng, Yang</creatorcontrib><creatorcontrib>Wan, Fu-Jian</creatorcontrib><creatorcontrib>Huang, You</creatorcontrib><creatorcontrib>Liao, Xing-Hua</creatorcontrib><creatorcontrib>Zhang, Tong-Cun</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncology reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hu, Hao</au><au>Xiang, Yuan</au><au>Zhang, Xiao-Yu</au><au>Deng, Yang</au><au>Wan, Fu-Jian</au><au>Huang, You</au><au>Liao, Xing-Hua</au><au>Zhang, Tong-Cun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CDCA5 promotes the progression of breast cancer and serves as a potential prognostic biomarker</atitle><jtitle>Oncology reports</jtitle><date>2022-10-01</date><risdate>2022</risdate><volume>48</volume><issue>4</issue><artnum>172</artnum><issn>1021-335X</issn><eissn>1791-2431</eissn><abstract>Cell division cycle-associated 5 (CDCA5) plays a critical role in the progression of various human cancers by regulating cell cycle-related proteins; however, the function of CDCA5 in breast cancer (BC) is poorly understood. The aim of the present study was to investigate the expression level of CDCA5 in BC and its effect on BC progression. CDCA5 was found to be highly expressed in patients with BC, as well as in BC cell lines. It was also found that a high CDCA5 expression in BC was significantly associated with a shorter survival rate. In addition, the expression level of CDCA5 was significantly increased in stem cells derived from suspension-cultured BC cells, as compared to adherent-cultured cells. CDCA5 knockdown in MCF7 and SKBR3 cells significantly reduced cell proliferation, migration and clone formation. At the same time, the stemness capacity of BC cells, determined by analyzing cancer stem cell marker expression and mammosphere formation, was also markedly diminished following the knockdown of CDCA5. In addition, in vivo experiments demonstrated that CDCA5 knockdown in MCF7 cells markedly reduced tumor growth. On the whole, the present study demonstrates that CDCA5 may be used as a prognostic biomarker and therapeutic target for BC.</abstract><cop>Athens</cop><pub>Spandidos Publications UK Ltd</pub><pmid>36004470</pmid><doi>10.3892/or.2022.8387</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1021-335X |
| ispartof | Oncology reports, 2022-10, Vol.48 (4), Article 172 |
| issn | 1021-335X 1791-2431 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9478967 |
| source | EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Biomarkers Biotechnology Breast cancer Cell growth Kinases Medical prognosis |
| title | CDCA5 promotes the progression of breast cancer and serves as a potential prognostic biomarker |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T21%3A48%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CDCA5%20promotes%20the%20progression%20of%20breast%20cancer%20and%20serves%20as%20a%20potential%20prognostic%20biomarker&rft.jtitle=Oncology%20reports&rft.au=Hu,%20Hao&rft.date=2022-10-01&rft.volume=48&rft.issue=4&rft.artnum=172&rft.issn=1021-335X&rft.eissn=1791-2431&rft_id=info:doi/10.3892/or.2022.8387&rft_dat=%3Cproquest_pubme%3E2706719622%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2716440753&rft_id=info:pmid/36004470&rfr_iscdi=true |